![In a press conference held at Lunit headquarters in Gangnam-gu, Seoul on the 2nd, Seo Beom-seok, CEO of Lunit, recently announced the meaning of raising capital through a paid-in capital increase for shareholders and the company's future growth strategy. [LUNIT]](https://foundernews.eu/storage/2026/02/news-p.v1.20260202.273c538db27941bb84644e3c59513dbd_P1.png)
Revenue growth of 40% to 50% year-on-year this year
Lunitscope sales exceeded 10 billion last year
Expected to increase by 2-3 years year-on-year this year
![In a press conference held at Lunit headquarters in Gangnam-gu, Seoul on the 2nd, Seo Beom-seok, CEO of Lunit, recently announced the meaning of raising capital through a paid-in capital increase for shareholders and the company's future growth strategy. [LUNIT]](https://wimg.mk.co.kr/news/cms/202602/02/news-p.v1.20260202.273c538db27941bb84644e3c59513dbd_P1.png)
Medical artificial innotifyigence (AI) company Lunit will resolve financial risks through a paid-in capital increase worth 250 billion won and speed up profitability improvement with the aim of achieving a surplus based on cash operating income (EBITDA) at the conclude of this year.
Lunit held a press conference on the 2nd and explained the background of the recent paid-in capital increase for shareholders and its future growth strategy. CEO Seo Beom-seok stated on the same day, “We will resolve financial uncertainty through the accumulation and enter a sustainable growth trajectory.”
Lunit entered the U.S. market by issuing convertible bonds worth 171.5 billion won in May 2024 and acquiring Volpara (currently Lunit International), a U.S. AI breast cancer diagnostic company. However, concerns over financial burden have been raised as the possibility of exercising the right to claim early repayment (put option) included in convertible bonds has been highlighted.
Accordingly, Lunit chose to increase the shareholder allocation paid-in capital increase. The company explained that the capital increase will eliminate the risk of potential cash outflows from put options and ease additional capital raising pressures. In particular, as the bequest funds are recognized as capital, they will also be free from the so-called “risk of legal losses” due to the loss of corporate tax losses.
The performance improvement trconclude is continuing. Lunit recorded 83.1 billion won in consolidated sales in 2025, up 53% from the previous year (54.2 billion won). The company predicted that sales will grow 40-50% year-on-year this year.
In the cancer diagnosis business sector, synergy with Volpara is in full swing. The number of new contracts for integrated breast cancer screening and full-cycle AI solutions exceeded 380 as of the conclude of 2025, with sales in the overall cancer diagnosis segment, including existing Volpara contracts, expected to increase 20% to 30%.
Lunit Scope, a cancer treatment business division, is also continuing to grow. It exceeded 10 billion won in sales for the first time last year, and more than 15 global pharmaceutical companies recorded cumulative sales since the launch of research products. Among them, some global pharmaceutical companies recorded more than 5 billion won in cumulative sales. The company expects Lunitscope sales to increase two to three times this year compared to the previous year.
On the other hand, the cost structure has been drastically revised. Since last year, Lunit has been undergoing restructuring and cost-efficiency to reduce about 15% of its total workforce, and plans to reduce operating costs by 20% year-on-year this year. Through this, it aims to achieve a break-even point (BEP) based on EBITDA at the conclude of the year.
CEO Seo stated, “This paid-in capital increase will be Lunit’s last capital raising,” adding, “This year will be a turning point in proving profitability and financial indepconcludeence.” He added, “We will do our best to enhance shareholder value by strengthening our competitiveness in the global medical AI market.”
Leave a Reply